Live Earnings Conference Call: PTC Therapeutics will host a live Q1 2025 earnings call on May 6, 2025 at 4:30PM ET. Follow this link to get details and listen to PTC Therapeutics' Q1 2025 earnings call when it goes live. Get details. PTC Therapeutics (PTCT) News Today $40.65 -9.30 (-18.62%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$41.04 +0.40 (+0.97%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Tudor Investment Corp ET AL Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Tudor Investment Corp ET AL raised its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,151 shares of the biopharmaceuticalMay 6 at 4:31 AM | marketbeat.comPTC Therapeutics stock drops after Huntington’s study updateMay 5 at 4:58 PM | investing.comPTC518 PIVOT-HD Study Achieves Primary EndpointMay 5 at 7:00 AM | prnewswire.comSchonfeld Strategic Advisors LLC Sells 66,953 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Schonfeld Strategic Advisors LLC lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 35.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 122,280 shares of the biopharmaceuMay 5 at 5:10 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from BrokeragesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fifteen analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommeMay 5 at 4:26 AM | marketbeat.comPrice T Rowe Associates Inc. MD Trims Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Price T Rowe Associates Inc. MD lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 9.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 509,204 shares of the biopharmMay 4 at 4:10 AM | marketbeat.comPTC Therapeutics (PTCT) to Release Earnings on TuesdayMay 4 at 1:07 AM | americanbankingnews.comEquities Analysts Issue Forecasts for PTCT FY2026 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of PTC Therapeutics in a report released on Tuesday, April 29th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($2May 3 at 8:54 AM | marketbeat.comSusquehanna Fundamental Investments LLC Takes $1.43 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Susquehanna Fundamental Investments LLC purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 31,670 shares ofMay 3 at 5:08 AM | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Bought by First Trust Advisors LPFirst Trust Advisors LP grew its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 24.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 133,763 shares of the biopharmaceutical company's stock afMay 3 at 4:02 AM | marketbeat.comRaymond James Financial Inc. Invests $2.20 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Raymond James Financial Inc. bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 48,728 shares of the biopharmaceutical company's stMay 3 at 3:38 AM | marketbeat.com9,492 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Nebula Research & Development LLCNebula Research & Development LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 9,492 shares of the biopharmaceutical company's stock, valued at approxMay 2, 2025 | marketbeat.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | prnewswire.comPDT Partners LLC Cuts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)PDT Partners LLC trimmed its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 44.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,081 shares of the biopharmaceutical comMay 1, 2025 | marketbeat.comNotable Monday Option Activity: PTCT, EOLS, NOWApril 30, 2025 | nasdaq.comAquatic Capital Management LLC Purchases 59,569 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Aquatic Capital Management LLC grew its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 578.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69,869 shares of thApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $13.85 Million Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Adage Capital Partners GP L.L.C. lifted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,756 shares of the biophaApril 30, 2025 | marketbeat.comTeachers Retirement System of The State of Kentucky Invests $940,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)Teachers Retirement System of The State of Kentucky purchased a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 20,822 sApril 30, 2025 | marketbeat.comTower Research Capital LLC TRC Boosts Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Tower Research Capital LLC TRC raised its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3,636.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,553 shares of the biopharmaceutical company's stock after buyingApril 29, 2025 | marketbeat.comInvesco Ltd. Has $5.03 Million Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Invesco Ltd. grew its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 107.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 111,391 shares of the biopharmaceutApril 28, 2025 | marketbeat.comWells Fargo & Company MN Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Wells Fargo & Company MN grew its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 43.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,148 shares of the biopharmaceutical company's stocApril 28, 2025 | marketbeat.comPTC Therapeutics Get Positive CHMP Opinion For Sephience For The Treatment Of PhenylketonuriaApril 27, 2025 | nasdaq.comCanada Pension Plan Investment Board Makes New Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)Canada Pension Plan Investment Board bought a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,500 shaApril 27, 2025 | marketbeat.comGuggenheim Capital LLC Lowers Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Guggenheim Capital LLC cut its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 22.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,486 shares of the biopharmaceutical company'sApril 26, 2025 | marketbeat.comPTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)April 25, 2025 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $136,666.96 in StockApril 25, 2025 | insidertrades.comPTC Therapeutics' (PTCT) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and set a $65.00 price target on shares of PTC Therapeutics in a research report on Tuesday.April 24, 2025 | marketbeat.comPTC Therapeutics to Participate at Upcoming Investor ConferencesApril 24, 2025 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Short Interest UpdatePTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,420,000 shares, a growth of 26.0% from the March 15th total of 4,300,000 shares. Approximately 7.4% of the shares of the company are short sold. Based on an average daily volume of 871,300 shares, the days-to-cover ratio is currently 6.2 days.April 22, 2025 | marketbeat.comRBC sees Makary interview as potentially positive for biotech stocksApril 22, 2025 | markets.businessinsider.comAlpha DNA Investment Management LLC Buys Shares of 10,258 PTC Therapeutics, Inc. (NASDAQ:PTCT)Alpha DNA Investment Management LLC purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 10,258 shares of the biopharmaceutical company's stock, valued atApril 21, 2025 | marketbeat.comXTX Topco Ltd Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)XTX Topco Ltd bought a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 13,223 shares of the biopharmaceutical company's stock, valued at approximately $597,000. Several other hedge funApril 21, 2025 | marketbeat.comJump Financial LLC Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Jump Financial LLC purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 62,809 shares of the biopharmaceutical company's stock, valued at approximately $2,April 20, 2025 | marketbeat.comWalleye Capital LLC Invests $4.97 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Walleye Capital LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 110,004 shares of the biopharmaceutical company's stApril 19, 2025 | marketbeat.comPTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on ThursdayPTC Therapeutics (NASDAQ:PTCT) will be releasing earnings before the market opens on Thursday, April 24, Financial Modeling Prep reports.April 19, 2025 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Up 6.8% - Time to Buy?PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.8% - What's Next?April 17, 2025 | marketbeat.comPTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial ResultsApril 17, 2025 | prnewswire.comRussell Investments Group Ltd. Reduces Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Russell Investments Group Ltd. reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 26.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 170,697 shares of the biopharmaceutiApril 15, 2025 | marketbeat.comFederated Hermes Inc. Invests $2.16 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT)Federated Hermes Inc. bought a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 47,828 shares of the biopharmaceutiApril 15, 2025 | marketbeat.comRenaissance Technologies LLC Acquires 114,900 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Renaissance Technologies LLC raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 21.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 653,100 shares of the biopharmaceutical company's stock after buyinApril 14, 2025 | marketbeat.comAlliancebernstein L.P. Increases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Alliancebernstein L.P. raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 62.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 361,644 shares of the biopharmaceutical compApril 11, 2025 | marketbeat.comADAR1 Capital Management LLC Raises Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)ADAR1 Capital Management LLC boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 140.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,023 shares of the biopharmaceutical compApril 9, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, fourApril 9, 2025 | marketbeat.comAmerican Century Companies Inc. Buys 24,090 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)American Century Companies Inc. increased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 66.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,150 shares of the biopharmaceuticalApril 9, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: PTC Therapeutics (PTCT) and Qiagen (QGEN)April 7, 2025 | markets.businessinsider.comHeadlands Technologies LLC Increases Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Headlands Technologies LLC boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 843.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,228 shares of the biopharmaceutical company's stApril 7, 2025 | marketbeat.comLee Scott Golden Sells 897 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 897 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $46.95, for a total transaction of $42,114.15. Following the completion of the sale, the executive vice president now directly owns 75,997 shares of the company's stock, valued at approximately $3,568,059.15. This trade represents a 1.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.April 6, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 897 SharesApril 5, 2025 | insidertrades.comWellington Management Group LLP Sells 3,105,676 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Wellington Management Group LLP lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,787,123 shares of the biopharApril 4, 2025 | marketbeat.comVanguard Group Inc. Buys 53,688 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Vanguard Group Inc. lifted its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 0.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,178,822 shares of the biopharApril 4, 2025 | marketbeat.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼1.270.72▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼217▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News GMAB News RDY News MRNA News ASND News VTRS News QGEN News ROIV News RVMD News LNTH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTCT Stock Free PTCT Stock Alerts